Thematic area:
Decision Support & Clinical Pathway Innovation
Product:
An AI-enabled spatial pathology classifier that analyses immune–tumour cell organization on histology slides to determine whether chemotherapy is required for early-stage ER+/HER2 breast cancer. The system provides higher precision than current genomic tests.
Market:
The global IVD oncology diagnostics market (~$100B) is rapidly expanding with demand for next generation prognostic tools. Customers include pathology labs, oncology departments, diagnostics companies, and personalised medicine providers.
Fit:
Current tests (e.g., Oncotype DX) have limitations, especially for pre-menopausal patients. This new classifier delivers improved accuracy, operates on widely available tissue slides, and integrates into digital pathology workflows. It has strong IP potential and clear licensing opportunities for major diagnostics firms.
